Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Lunai Bioworks Inc

LNAI ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$0.16

▼ -30.20%

Market Cap $829.68K · Vol 300.14K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$829.68K

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

3.97

Momentum

Beta

0.16

vs Market

52W High

$13.12

98.74% below

52W Low

$0.15

12.11% above

Volume

300.14K

Avg 58.94K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

62.52%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Lunai Bioworks Inc (LNAI) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does LNAI pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-64.94%

-90.69%

-92.19%

-93.81%

YTD

-97.66%

-97.85%

-99.93%

-99.98%

Financials & Valuation

TTM · Annual

Total Revenue	$51.99K
Net Income	$-3,562,480.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-15,129.29%
Net Profit Margin	-6,851.98%
ROE	N/A
ROA · ROIC	-39.21% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	211.38
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	5.03M

Technical Indicators

50-Day SMA	$1.61
200-Day SMA	$2.91
RSI (14)	3.97
Beta	0.16
52-Week High	$13.12
52-Week Low	$0.15

Volume Today	300.14K
Avg Daily Volume (30D)	58.94K
Relative Volume	5.09x
Volatility (10D)	270.38
Volatility (30D)	194.12
Free Float	62.52%

Analyst Consensus

N/A

Current Price $0.16

Mean Target N/A

52W Low$0.15 52W High$13.12

Current

Target

$0.15 $13.12

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG0060CNMH7

ISINUS29350E3027

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.63% ONC BeOne Medicines AG +2.51% 068270.KS Celltrion, Inc. +7.50% MEDP Medpace Holdings, Inc. -3.32% ICLR ICON PLC -0.72%

Company Profile

Lunai Bioworks, Inc is focused on AI-powered biodefense, drug discovery and advanced diagnostics. It is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. Its segments include RENB, BioSymetrics and RENC. The RENB segment is engaged in developing new immunotherapies to combat cancer. BioSymetrics is engaged in integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine. RENC is developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform.